Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP... Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Mehr anzeigen
-- Company Expects to Complete BLA Submission by End of 1Q 2025 -- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.09 | -2.7027027027 | 3.33 | 3.395 | 2.99 | 1317070 | 3.20129275 | CS |
| 4 | 0.01 | 0.30959752322 | 3.23 | 3.825 | 2.99 | 1362637 | 3.40539374 | CS |
| 12 | -1.06 | -24.6511627907 | 4.3 | 4.33 | 2.815 | 1433043 | 3.47631474 | CS |
| 26 | -0.57 | -14.9606299213 | 3.81 | 5.11 | 2.815 | 1617438 | 3.9175391 | CS |
| 52 | -1.42 | -30.4721030043 | 4.66 | 5.7 | 2.815 | 1249561 | 4.19164592 | CS |
| 156 | 2.08 | 179.310344828 | 1.16 | 5.7 | 1.02 | 620546 | 3.75342112 | CS |
| 260 | 1.77 | 120.408163265 | 1.47 | 6.48 | 0.9952 | 814767 | 2.9721464 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
